Zdrowie i gospodarka · 22/07/2024
FDA Releases Guidance for COVID-19 Convalescent Plasma Manufacturing
The FDA has released a final guidance for the industry on submitting a Biologics License Application (BLA) for COVID-19 convalescent plasma intended for transfusion in immunosuppressed patients, and for investigational new drug applications (INDs) for investigational COVID-19 convalescent plasma.